Stockwinners Market Radar for February 09, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:02 EST Roblox, NFL partner to expand metaverse presence - The National Football League and Roblox "announced the launch of NFL Tycoon to engage the next generation of NFL football fans in the Metaverse. The NFL will be the first official major sports league to offer a persistent experience on Roblox, a global platform bringing millions of people together through shared experiences."

18:12 EST Western Digital says material contamination affecting production operations - Western Digital announced that contamination of certain material used in its manufacturing processes has occurred and is affecting production operations at both its Yokkaichi and Kitakami joint venture, flash fabrication facilities. Western Digital's current assessment of the impact is a reduction of its flash availability of at least 6.5 exabytes. The company is working closely with its joint venture partner, Kioxia, to implement necessary measures that will restore the facilities to normal operational status as quickly as possible.

18:10 EST Embraer announces contract amendments with Brazilian Air Force - Embraer hereby updates the information disclosed in the Notice to the Market on November 12, 2021 regarding the contracts 002/DCTA-COPAC/2014 and 10/DCTA-COPAC/2014, entered into in 2014 among the Brazilian Federal Government, Embraer and one of its subsidiaries. After the disclosure of the afore mentioned Notice to the Market, Embraer and the Brazilian Air Force engaged in intense discussions on the subject, the complexity of which required a large number of meetings with the participation of various representatives of both parties. The successful negotiation process resulted in the execution of amendments to the contracts to, among other matters, (i) reduce from 28 to 22 the total number of KC-390 Millennium aircraft to be delivered under the terms of the contracts; and (ii) adjust other contractual clauses as compensation for the reduction mentioned in the previous item to mitigate the impacts for the company. The company's Management estimates that the result of the negotiations reflected in the amendments to the contracts will generate a reduction in the backlog of approximately $500M. Such amendments may result in an immediate impact on Embraer's operating results of up to $50M and will be reflected in the 2021 Financial Statements, with no immediate effect on the company's cash account. We emphasize that the impacts in 2021 do not compromise the achievement of the guidance disclosed by the company for the year 2021. Embraer reiterates its commitment to the KC-390/C-390 Millennium project, a new generation multi-mission aircraft, as well as its belief in the export potential of this product, which brings unique innovations in its category and which has already been acquired by two European nations.

18:03 EST ITT raises quarterly dividend 20% to 26.4c per share - The company also announced that it is increasing its quarterly dividend 20% to 26.4c per share on the company's outstanding common stock. ITT's Board of Directors approved the cash dividend for the first quarter of 2022, which will be payable on April 4 , to shareholders of record as of the close of business on March 9 .The 20% increase in the quarterly dividend announced follows increases of 15% and 30% announced in 2020 and 2021.

17:28 EST Boeing awarded $99.83M Air Force contract - Boeing has been awarded a $99.83M indefinite-delivery/indefinite-quantity contract for engineering support services. This contract provides for engineering services and support for recurring and non-recurring requirements relating to the E-3 Sentry Airborne Warning and Control System. Work will be performed in Oklahoma City, Oklahoma, and is expected to be completed by August 9, 2028. This contract involves 40% Foreign Military Sales to NATO, Saudi Arabia, United Kingdom, and France, and is the result of a sole-source acquisition. FY22 operations and maintenance funds in the amount of $455,782 are being obligated at the time of award. Air Force Life Cycle Management Center is the contracting activity.

17:21 EST Lockheed Martin awarded $315.81M Navy contract modification - Lockheed Martin was awarded a not-to-exceed $315.81M fixed-price incentive, cost-plus-incentive-fee, and cost-plus-fixed-fee, undefinitized modification to a previously awarded contract. This modification adds scope for the procurement, delivery, installation, and configuration of F-35 Joint Strike Fighter support equipment and non-aircraft spares. Additionally, this modification provides for site activations and integrated contractor support for the Air Force, Marine Corps, Navy, non-U.S. Department of Defense participants and Foreign Military Sales customers. Work is expected to be completed in December 2027. FY22 aircraft procurement funds in the amount of $44.23M; FY22 aircraft procurement funds in the amount of $5.67M; FY21 aircraft procurement funds in the amount of $100.38M; FMS customer funds in the amount of $10.33M and non-U.S. DOD partner funds in the amount of $2.22M will be obligated at the time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:08 EST Taysha Gene Therapies' CLN7 Batten disease treatment shows positive safety data - Taysha Gene Therapies announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the 18th Annual WORLD Symposium by investigators from UT Southwestern. Safety data demonstrated that the first-generation construct was well-tolerated at multiple doses including the highest dose administered in humans ever for a gene therapy product. No adverse immune responses have been noted, including no evidence of dorsal root ganglion toxicity or brain inflammation across all subjects. Moreover, stabilization in sural nerve conduction supported the absence of dorsal root ganglia inflammation. Complete blood counts revealed no signs of bone marrow suppression or clinically significant bone marrow reactivity, and cerebral spinal fluid analysis revealed no signs of pleocytosis. Taysha holds the exclusive option to license the CLN7 Batten disease program from UT Southwestern. CLN7 Batten disease is a rare, fatal, and rapidly progressive neurodegenerative disease that is a form of Batten disease. Currently, there are no approved therapies to treat CLN7 Batten disease, which impacts an estimated 4,000 patients globally.

17:04 EST Merck announces publication of KEYNOTE-522 trial data - Merck announced the publication of results from the Phase 3 KEYNOTE-522 trial in the February 10 edition of the New England Journal of Medicine. Results showed that neoadjuvant Keytruda, Merck's anti-PD-1 therapy, in combination with chemotherapy followed by adjuvant Keytruda as monotherapy, significantly prolonged event-free survival compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer.

17:03 EST Five Point Holdings appoints Daniel Hedigan as CEO, COO stepping down - Five Point Holdings appointed CEO Daniel Hedigan effective immediately. Lynn Jochim, COO, will step down, effective as of February 14. Most recently, Hedigan served as President of Land Sales & Home Building at the Irvine Company from 2013 to 2021. Jochim has agreed to assist the company going forward under an advisory agreement with a term of three years.

17:02 EST First American names Ken DeGiorgio as CEO, succeeding Dennis Gilmore - First American Financial announced that Kenneth DeGiorgio, who most recently served as the company's president, has been appointed CEO, while Dennis Gilmore, First American's CEO since 2010, transitions to become chairman of the board of directors. DeGiorgio was named president in May 2021, when he assumed responsibility for the corporation's operating groups, including its title insurance, specialty insurance and data and analytics businesses. Since joining the company in 1999, DeGiorgio has at various times in his tenure overseen the company's banking operations, international division and multiple corporate functions.

16:58 EST PFSweb receives Nasdaq delisting notice - PFS announced that, as expected, on February 8, 2022, it received a determination notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that unless the company requests a hearing before the Hearings Panel by February 15, 2022, trading in the company's common stock would be suspended and subject to delisting based upon its non-compliance with Nasdaq's filing requirement, as set forth in Listing Rule 5250(c)(1). The Notice was issued in accordance with standard Nasdaq procedures due to the delayed filing of the company's Form 10-Q for the period ended September 30, 2021. The company intends to request, prior to the February 15, 2022 deadline, a hearing before the Panel to request a stay of the Staff's delisting determination. As a result of the filing the Request, the delisting of the company's common stock will be automatically stayed for fifteen days from the Request. If the Panel grants the company's request for a stay, any final delisting action will be further stayed until at least the Panel's final determination following the hearing. At the hearing, which is generally held within 30 to 45 days after the Request, the company will present its plan to regain compliance with the Rule and request the continued listing of its common stock on Nasdaq Capital Market pending such compliance. There can be no assurance that the Panel will grant the company's requests.

16:54 EST Strata Skin Sciences launches Xtrac Momentum 1.0 - Skin Sciences announced its commercial launch, with the first installation in the U.S. market, of its next generation excimer laser system, Xtrac Momentum 1.0.

16:50 EST Correct: Uber reports Q4 EPS 44c, consensus (35c) - Reports Q4 revenue $5.78B, consensus $5.34B. "Our results demonstrate just how far we've come since the beginning of the pandemic," said Dara Khosrowshahi, CEO. "In Q4, more consumers were active on our platform than ever before, Delivery reached Adjusted EBITDA profitability, and Mobility Gross Bookings approached pre-pandemic levels. While the Omicron variant began to impact our business in late December, Mobility is already starting to bounce back, with Gross Bookings up 25% month-on-month in the most recent week."

16:44 EST Range Resources reports Q4 production averaged 2m187 Mmcfe per day - Range Resources announced that fourth quarter 2021 production averaged approximately 2,198 Mmcfe per day, and fourth quarter 2021 all-in capital spending totaled $92.3 million. In addition, Range realized $29.5 million in contingent derivative settlement gains in fourth quarter 2021. Fourth quarter 2021 daily natural gas production averaged approximately 1,534 Mmcf per day. The average natural gas realization, including the impact of basis hedges, was $5.38 per mcf, the highest quarterly pre-hedge realization since 2014. The average natural gas price, including settled index hedges, was $3.27 per mcf. In addition, Range realized a contingent derivative settlement gain of $20 million related to natural gas prices in 2021. Fourth quarter 2021 daily NGL production averaged approximately 102,126 barrels per day. Pre-hedge NGL realizations were $36.26 per barrel, the highest quarterly pre-hedge NGL realization since 2013. The average NGL price, including settled index hedges, was $34.77 per barrel. In addition, Range realized a contingent derivative settlement gain of $6 million related to NGL prices in 2021. Fourth quarter 2021 daily oil and condensate production averaged approximately 8,674 barrels per day. Crude oil and condensate price realizations, before realized hedges, averaged $70.07 per barrel, the highest quarterly pre-hedge realization since 2014. The average condensate price, including settled index hedges, was $52.56 per barrel. In addition, Range realized a contingent derivative settlement gain of $3.5 million related to WTI prices. Fourth quarter 2021 drilling and completion expenditures were $83.7 million.

16:40 EST Mattel jumps 10% to $25.05 after Q4 results, FY22 guidance beat estimates - The company also raised its FY23 revenue outlook.

16:38 EST Oasis Petroleum sees Q4 production 68.8 MBoepd - Sees Q4 oil production volumes of 44.4 Mbopd. "Capital discipline and shareholder returns are central tenants of our strategy," said CEO Danny Brown. "Given our high quality assets with low breakeven pricing, and very strong financial position, this fixed-dollar program demonstrates our commitment to shareholder returns while retaining flexibility to participate in industry consolidation or fund organic growth opportunities should prices and conditions warrant. Oasis returned over $210M of capital to shareholders in 2021 and the new program builds on that strong foundation with an approximate 33% year-over-year increase. Preliminary Q4 results demonstrate our commitment to cost control and return of capital to shareholders. Capital expenditures and expenses were favorable to expectations while delivering volumes inside of guidance with strong price realizations."

16:35 EST EQT Corporation sees Q1 total sales volume 475-525 Bcfe

16:32 EST Weatherford announces realignment of reporting structure - Weatherford announced a segment recast by quarter for the full year 2020 and through the third quarter of 2021. Effective the fourth quarter of 2021, Weatherford realigned its reporting structure to three product line segments (1) Drilling and Evaluation (2) Well Construction and Completions, and (3) Production and Intervention. The updated structure further refines the company's organizational focus and business strategy around the well life cycle and is intended to drive improved customer collaboration and growth opportunities. All segments provide services to core oil and gas as well as new energy markets. As a result, beginning with the announcement of the company's fourth quarter of 2021 results and its Annual Report on Form 10-K for the year ended December 31, 2021, Weatherford will report its results in these three reportable segments. All other segments, corporate and other expenses that do not individually meet the criteria for segment reporting will be combined and reported separately. Additionally, we have changed our primary measure of segment profitability to be segment adjusted EBITDA, which is based on segment earnings before interest, taxes, depreciation, amortization, share-based compensation expense and other adjustments. The change in segment reporting had no impact on the company's consolidated revenue, income before taxes, net income, or earnings per share for any period.

16:27 EST Enova International announces $100M share repurchase program - Enova announced that its Board of Directors has authorized a share repurchase plan for up to $100M of its common stock. This new program will be in place until June 30, 2023. The existing $150M repurchase program will terminate and be replaced by this new program. Through February 8, 2022, Enova had repurchased $133M in common stock under the terminating program.

16:23 EST DCP Midstream sees FY22 net income $615M-$765M, adjusted EBITDA $1.34B-$1.5B

16:21 EST AeroVironment awarded $10.5M contract - AeroVironment announced it received a $10,534,348 firm-fixed-price U.S. Department of Defense Foreign Military Sales contract award on Jan. 21, 2022. The contract includes the delivery of Puma(TM) LE small unmanned aircraft systems over a six-year period to an allied nation, as well as add-on air vehicle kits, initial spares packages, training and support.

16:21 EST Regional Management announces new stock repurchase program of up to $20M - The company's Board of Directors has authorized a new stock repurchase program allowing for the repurchase of up to $20 million of its outstanding common stock. The authorization is effective immediately and will continue through February 3, 2024.

16:21 EST Invesco reports preliminary AUM $1.55T as of January 31 - A decrease of 3.7% versus previous month-end. The firm achieved net long-term inflows of $8.5B this month.

16:15 EST Quotient expects relationship with Albertsons to wind down in Febraury - The company said, "We expect our relationship with Albertsons Companies, Inc. to wind down by the end of February. We have been focused on implementing cost cutting measures in advance of their transitioning off our platform and will continue to lower our operating expenses over the course of the year."

16:13 EST U.S. Xpress Enterprises sees 'robust' freight market moderating as year goes on - The company said: "We expect a robust freight market early in the year that moderates as the year goes on, due to improvements in the supply chain, inventory restocking, and perhaps some slowing of manufacturing and imports based on Fed tightening and a return to consumer spending on services. At the same time, shortages of drivers and new tractors and trailers should limit capacity expansion. We expect this to result in meaningful increases in OTR contract rates and to a lesser extent in Dedicated, at least in the first half of the year. The rate increase benefit likely will be offset in significant part by inflation, some of which is already embedded in our costs, with more to come. Based on our macro expectations, improvements in our operating results are likely to come primarily from improvements in OTR per tractor utilization, better freight selection when more freight is being run through the Optimizer, and better fixed cost coverage through increases in total fleet size and miles. The good news is much of this is under our control, and I believe we have the right team in the right jobs with the right plan for success. The pace of our success will be apparent in the results of turnover, safety, revenue per tractor, and eventually total seated tractor count, primarily in Variant but also across our entire Truckload segment."

16:12 EST Envista sees FY22 core growth 6%-8% - The company said, "For 2022, barring any significant COVID related disruptions, we expect to deliver core growth of between 6-8% and deliver a full year adjusted EBITDA margin of greater than20%. It is important to note that our guidance does not reflect the impact of the pending acquisition of Carestream Dental's IOS business. We currently expect this acquisition to close in Q2 2022 and will provide updated guidance related to the underlying business as well as our planned integration and growth related investments once we have closed the transaction."

16:10 EST Endra Life Sciences to pursue De Novo pathway for TAEUS system - Endra Life Sciences announced it will build on the content of its completed 510(k) application and pursue the De Novo pathway for its TAEUS System, which is intended to characterize fatty liver tissue as a means to non-invasively assess and monitor Non-Alcoholic Fatty Liver Disease. ENDRA's updated regulatory strategy is the result of a tremendous amount of productive dialogue with the U.S. Food and Drug Administration (FDA), which led to a clearer understanding of the path forward to achieve ENDRA's U.S. market claims for the TAEUS System. While ENDRA could continue to pursue its 510(k) application, ENDRA now believes that the potential resulting 510(k) market claims may understate the TAEUS System's clinical and commercial value. This is particularly so when ENDRA considers the remaining effort to demonstrate 510(k) predicate equivalency compared with the effort involved in the De Novo pathway. For a similar investment of time and effort, ENDRA believes it can achieve a stronger market position through the De Novo process with TAEUS-optimized market claims compared with the 510(k) approach. ENDRA's De Novo submission will involve the following key steps: Leveraging substantial portions of ENDRA's completed 510(k) submission, which encompasses many of the same elements as the intended De Novo submission, including safety and efficacy data; Customizing TAEUS' proprietary testing methods into "special controls," which will become requirements for future product submissions. This is expected to accelerate 510(k) submissions of future generations of TAEUS products while creating market-entry barriers for competitive products; Adding limited confirmatory clinical data from a subset of ENDRA's existing clinical evaluation sites, which is expected to be available in 2022.

16:09 EST Disney up 10% after earnings and streaming subscribers beat expectations - Disney shares are up $14.67, or 10%, to $161.98 in after-hours trading following the company's Q1 report.

16:09 EST Twilio jumps 20% to $241.50 after sales outlook tops estimates

16:08 EST Disney reports 129.8M Disney+ paid subscribers as of January 1 - Reports Disney+ paid subscribers of 129.8M, up from 94.9M last year. Reports ESPN+ paid subscribers 21.3M vs. 12.1M last year. Reports total Hulu paid subscribers 45.3M vs. 39.4M last year.

16:06 EST Atlassian explores redomiciling from the U.K. to the U.S. - Atlassian Corporation announced it has undertaken an exploration of redomiciling its parent holding company from the United Kingdom to the United States. Atlassian believes moving its parent company to the United States will increase its access to a broader set of investors, support inclusion in additional stock indices, streamline its corporate structure, and provide more flexibility in accessing capital. Atlassian does not believe this transaction will result in any significant operational or business model changes. The transaction is subject to final approval, including by Atlassian's Board of Directors and shareholders. Pending exploration, Atlassian would aim to close the transaction in the first half of fiscal year 2023, and will share additional details in the coming months, including the filing of additional materials with the U.S. Securities and Exchange Commission.

16:02 EST Blue Bird says expecting challenging first of of 2022 - CFO Razvan Radulescu says: "We are expecting a challenging 1H for fiscal 2022 due to continued supply constraints and margin pressure, with the majority of the supplier cost increases taking effect on January 1, 2022. We still expect to see gradual relief beginning in fiscal Q3 as supply chain constraints are resolved due to new suppliers coming on board, and orders with the 11% price increase begin to be delivered. In Fiscal Q4 we expect to be at higher production levels and with normalized margins as the full 11% price increase goes into effect. Therefore, we are maintaining our guidance for fiscal 2022, previously released during our fiscal 2021 year-end call."

15:44 EST Douglas Elliman says 2021 total sales volume hit $51.2B in closed sales - Douglas Elliman Realty announces that the firm had "a record-breaking 2021." Nationwide sales totaled approximately $51.2B, which it called "the highest sales volume in ten years," with a total of approximately 32,400 sales transactions, "also the highest in a decade." Howard Lorber, Douglas Elliman Inc.'s CEO, said: "We are enormously proud of our unflagging agents, managers and staff across the country who all contributed to the enormous success we achieved in 2021. 2021 proved to be a banner year, culminating with our greatest listing yet: DOUG trading on the New York Stock Exchange."

15:35 EST Roblox up 10% after NFL announces launch of 'NFL Tycoon' experience - Shares of Roblox are up $6.20, or 10%, to $70.63 in late day trading after the company and the National Football League announced the launch of "NFL Tycoon" to "engage the next generation of NFL football fans in the Metaverse."

15:21 EST Tesla CEO says 'dropped the ball badly regarding new Model X production ramp' - In reply to a tweet about problems with the Model X rollout, Tesla CEO Elon Musk wrote: "We dropped the ball badly regarding new Model X production ramp & still haven't fully recovered. Was idiotic to stop production of old X in Dec 2020 when there was still plenty of demand!" Reference Link

15:05 EST Siemens to sell mail and parcel business to Koerber in EUR1.15B deal - Siemens has reached an agreement to sell the mail and parcel business of Siemens Logistics GmbH to the Koerber Group. With this transaction, approved by the Managing and Supervisory Boards of Siemens AG, Siemens is further implementing the rigorous sharpening of its portfolio as a focused technology company. The purchase price totals an enterprise value of EUR1.15B. Closing is expected in the course of the current calendar year, subject to regulatory approvals. "We're continuously sharpening and optimizing our portfolio in order to further strengthen Siemens as a focused technology company. In Koerber, we're very pleased to have found for our employees and customers the ideal new owner for our mail and parcel business. Koerber's future-oriented strategy for growth, innovation and investment is in the best interests of all stakeholders," said Roland Busch, President and Chief Executive Officer of Siemens AG.

14:54 EST BridgeBio's Eidos cancels ATTRibute-PN study in patients with ATTR-PN - Eidos Therapeutics, a BridgeBio company, has canceled the ATTRibute-PN study, a Phase 3 study of the efficacy and safety of acoramidis in subjects with symptomatic Transthyretin Amyloid Polyneuropathy, or ATTR-PN, according to an update posted to the ClinicalTrials.gov website dated February 9. The recruitment status of the study is indicated to be "Withdrawn (Sponsor's decision to cancel study)," according to the site posting. Reference Link

13:54 EST Social justice group Global Justice Now says Pfizer 'profiteered' from pandemic - Global Justice Now, "a social justice group, campaigning for equitable access to Covid-19 vaccines," said partly, on its web site, the following:" Pfizer's annual revenue has doubled to $81B, more than the GDP of the majority of countries. If Pfizer were a country, it would have the 66th largest GDP in the world, ahead of countries like Ethiopia, Kenya, Ghana, Guatemala, Oman, and Luxembourg...Pfizer's bumper revenues are driven largely by their vaccine, which was first developed by smaller German company BioNTech with EUR 100m in debt financing from the publicly-owned European Investment Bank and a EUR 375m grant from the German government. Pfizer also received a $1.9B early order from the US government to de-risk R&D "The development of mRNA vaccines should have revolutionized the global covid response. But we've let Pfizer withhold this essential medical innovation from much of the world, all while ripping off public health systems with an eye-watering mark-up..."Right now, there are billions of people who cannot access Covid-19 vaccines and treatments. Many are in countries with the facilities needed to manufacture mRNA jabs, but Pfizer's jealous guarding of its patent stands in the way. And we're seeing thousands of preventable deaths each day as a result..."It's nothing short of pandemic profiteering for Pfizer to make a killing while its vaccines have been withheld from so many. Pfizer is now richer than most countries; it has made more than enough money from this crisis. It's time to suspend intellectual property and break vaccine monopolies." Reference Link

13:29 EST Duke Energy sees full exit from coal by 2035 - Duke Energy announced that it is taking additional steps toward action on climate change "while maintaining its commitment to reliable, accessible and affordable energy for customers and communities," including targeting energy generated from coal to represent less than 5% of total generation by 2030 and to fully exit coal by 2035 as "part of the largest planned coal fleet retirement in the industry." In addition, Duke said it is expanding its 2050 net-zero goals to now include Scope 2 and certain Scope 3 emissions: In its electric business, the company's net-zero goal will include greenhouse gas emissions from the power it purchases for resale, from the procurement of fossil fuels used for generation and from the electricity purchased for its own use; For the natural gas business, it means adding a new net-zero by 2050 goal that includes upstream methane and carbon emissions related to purchased gas and downstream carbon emissions from customers' consumption. Duke Energy Chief Sustainability Officer Katherine Neebe said: "The energy sector must transform for the future in a way that also benefits our society today. Achieving this vision will require us to transition to low- and zero-emissions fuel sources, invest in our communities and develop and prepare a diverse workforce. Taken together, these efforts will deliver long-term value for our stakeholders."

13:18 EST Stronghold Digital, Silvergate, Gannett mentioned as long ideas by Bill Miller - Bill Miller of Miller Value Partners discussed Vroom (VRM), Gannett (GCI), Stronghold Digital Mining (SDIG) and Silvergate Capital (SI) as among his long ideas while being interviewed on CNBC.

13:07 EST Microsoft to make 'Call of Duty' available on PlayStation beyond existing pacts - As part of a blog post about a new set of Open App Store Principles, Microsoft (MSFT) provided some additional details on how it will operate its store following the closing of its Activision Blizzard (ATVI) acquisition. "We also recognize that regulators may well have other important questions as they review our acquisition of Activision Blizzard," the company said. "We're committed to addressing every potential question, and we want to address publicly at the outset two such questions here. First, some commentators have asked whether we will continue to make popular content like Activision's Call of Duty available on competing platforms like Sony's (SONY)PlayStation. The obvious concern is that Microsoft could make this title available exclusively on the Xbox console, undermining opportunities for Sony PlayStation users. To be clear, Microsoft will continue to make Call of Duty and other popular Activision Blizzard titles available on PlayStation through the term of any existing agreement with Activision. And we have committed to Sony that we will also make them available on PlayStation beyond the existing agreement and into the future so that Sony fans can continue to enjoy the games they love. We are also interested in taking similar steps to support Nintendo's successful platform. We believe this is the right thing for the industry, for gamers and for our business." Reference Link

12:33 EST L'Oreal 'confident' in ability to outperform the market in 2022 - L'Oreal said: "In a global context that remains volatile at the beginning of the year, we are confident in our ability to outperform the market in 2022 and achieve another year of growth in both sales and profits."

12:16 EST Twitter joins $20M funding round for bitcoin payments provider OpenNode - In a company blog post, OpenNode said, "We are thrilled to announce the close of a $20M Series A funding round. With the close of this oversubscribed funding round, we will solidify our position as an industry-leading bitcoin payment processor and infrastructure provider for businesses, platforms, and people everywhere. UK-based Kingsway led the round, which also included Twitter, Tim Draper, and Avon Ventures, a venture capital fund affiliated with the parent company of Fidelity Investments. With the support of an incredible group of investors and partners, OpenNode will continue to focus on building Bitcoin and Lightning Network payments infrastructure that will catalyze Bitcoin's global adoption...With this investment, OpenNode will be able to rapidly expand our services and grow our team. In the next few weeks and months, we'll be announcing new product features, partnerships, and clients that will drive significant adoption of Bitcoin payments." Reference Link

12:01 EST Container Store falls -20.0% - Container Store is down -20.0%, or -$2.11 to $8.42.

12:00 EST New Relic falls -28.3% - New Relic is down -28.3%, or -$30.93 to $78.25.

12:00 EST Dingdong rises 19.7% - Dingdong is up 19.7%, or $1.17 to $7.08.

11:58 EST XPeng reports inclusion of shares in Shenzhen-Hong Kong Stock Connect Program - XPeng Inc. on Tuesday announced that the company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited, are included in the Shenzhen-Hong Kong Stock Connect programs, effective on February 9, according to the announcement issued by the Shenzhen Stock Exchange. Under the Stock Connect programs, qualified Mainland Chinese investors can access eligible Hong Kong shares, subject to specified daily quotas, XPeng said in a statement. "We are pleased to be included in the Stock Connect programs, which enable qualified Mainland Chinese investors to have direct access to our shares through the Stock Exchanges in the Mainland. The inclusion will not only further expand and diversify our investor base but also provide the opportunity for our customers, partners and EV and technology investors in China to participate in our exciting growth story," said Brian Gu, Vice Chairman and President of the Company.

11:23 EST Meta Platforms launches Split Payments, Vanish Mode on Messenger - Meta Platforms said Split Payments is now available in the U.S. on iOS and Android phones. To use Split Payments, tap the + icon in a group chat and select the payments tab, then tap the Get started button. From there you can split your bill evenly or customize the amount each person owes. Then, enter a personalized message, confirm your payment details, and send the request. Friends who are new to payments in Messenger can easily add payment details to send and receive money. The company is also launching new voice message recording controls so users can pause, preview, delete, or continue recording a voice message before sending. Additionally, it is increasing the duration of voice messages from one minute to 30 minutes. Meta also announced that user will be able to send disappearing messages with Vanish Mode. "With Vanish Mode, your messages disappear after they're seen. And if you can't find the right words, you can also send disappearing memes, GIFs, stickers or reactions. To turn on Vanish mode, open an existing chat thread on your mobile device and swipe up. Swipe up again, and you're back to your regular chat," the company explained.Reference Link

11:02 EST Cellcom Israel to terminate registration and SEC reporting obligations - Cellcom Israel announces that it intends to terminate the registration of its ordinary shares and its reporting obligations with the United States Securities and Exchange Commission. For this purpose, the company intends to file with the SEC a certification under Form 15F on February 9. Upon such filing, the company's reporting obligations with the SEC will be suspended immediately. The termination of the company's registration and reporting obligations is expected to become effective no later than 90 days after such filing if there are no objections from the SEC.

10:27 EST FDA issues draft guidance on developing non-opioid analgesics - The U.S. Food and Drug Administration announced that it "took new steps aimed at fostering the development of non-addictive alternatives to opioids to manage acute pain and decreasing exposure to opioids and preventing new addiction." The agency issued draft guidance to provide recommendations to companies developing non-opioid analgesics for acute pain lasting up to 30 days, typically in response to some form of tissue injury, such as trauma or surgery. "This guidance supports the HHS Overdose Prevention Strategy, which focuses on four priority areas - primary prevention, harm reduction, evidence-based treatment and recovery support... The guidance also fulfills certain legal requirements of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, commonly referred to as the SUPPORT Act. The SUPPORT Act directs the agency to issue or update existing guidance to help address challenges to developing non-addictive medical products to manage pain. The FDA is accepting public comments on the draft guidance documents until April 11," the agency said. Public companies developing non-opioid pain medicines include Pacira (PCRX), Collegium (COLL) and Cara Therapeutics (CARA).

10:15 EST Tritium Dcfc Ltd trading halted, volatility trading pause

10:02 EST UnitedHealth Dental launches digital resources, collaboration with quip - UnitedHealthcare Dental has introduced several enhancements designed to help people improve their oral health and access dental care in a more convenient and informed way, with the aim of helping lower costs and improve satisfaction among members and dental professionals. The latest offering expands access to 24/7 Virtual Dental Visits to help members meet with a licensed dentist via phone or video, giving eligible members in many UnitedHealthcare Dental plans two virtual dental appointments with no cost sharing. The enhanced virtual dental care benefit is designed to improve access to dental advice anywhere and anytime, which may help avoid often-unnecessary visits to the emergency department for oral health issues. In addition, to help people improve their oral care habits, millions of UnitedHealthcare Dental members can now save up to 30% on smart electric toothbrushes from oral health company quip. Additionally, UnitedHealthcare Dental members now have access to an online resource to help bring greater transparency to treatment options and the cost of dental care, with the goal of helping prevent surprise costs.

09:57 EST CDRO Stock trading resumes

09:50 EST Evolution Petroleum acquires natural gas assets in Wyoming for $29.4M - Evolution Petroleum has entered into a definitive agreement to acquire non-operated natural gas assets in the Jonah Field in Sublette County, Wyoming from privately-owned Exaro Energy III. The purchase price of the Transaction is $29.4M, subject to customary purchase price adjustments and closing conditions, including receipt of all necessary written consents, approvals, waivers, and any exercises of preferential purchase rights. The effective date of the Transaction is February 1, 2022 with a closing date on or about April 1, 2022. The asset includes an average working interest of 19.3% and an average revenue interest of 14.7% interest in 648 producing wells and approximately 1,040net acres in the Jonah Field in Sublette County, Wyoming. Jonah Field is a historically prolific, long term natural gas field located within the greater Green River Basin. Current net daily production of the acquired asset is approximately 14.2MMCFepd with a commodity split of 88% natural gas, 6% oil, and 6% NGLs. All wells are operated by Jonah Energy, which is an established operator in Wyoming and has operated in the field since 2014. The asset was evaluated solely on the basis of current production, or PDP basis. Evolution expects to add 42 BCFe of long-life PDP reserves at $0.70per MCFe cost. Evolution considers the gas marketing optionality to be an attractive and risk-reducing attribute of the acquired assets. Natural gas produced in the Jonah Field can be sold to western markets through the Opal hub, and have recently traded at a premium to Henry Hub. Natural gas can also be moved and sold to eastern and Gulf Coast markets as well, which reduces the risk of pipeline takeaway capacity access. Evolution plans to fund the Transaction with cash on hand and borrowings under the Company's existing senior secured credit facility with MidFirst Bank. Effective November 9, 2021, the Company's borrowing base was increased to $50M, with an elected commitment amount of $40M. As of December 31, 2021 and prior to the transaction, the Company had approximately $13M in cash on hand and had $4M drawn under the credit facility. The Company estimates that net debt after giving effect to the Transaction, in addition to the recently announced Williston Basin transaction, will be below the Company's targeted maximum of one times pro forma Adjusted annual EBITDA. The credit facility agreement requires the Company to enter into hedges covering a portion of oil and natural gas production on a rolling twelve-month basis depending on the level of debt.

09:30 EST Cryoport expects to resume production at New Prague facility during Feb. 14 week - Cryoport provided an update on resumption of activities at the New Prague facility. As previously announced, a fire occurred in a portion of the MVE Biological Solutions manufacturing facility located in New Prague, Minnesota on January 25, causing production to be temporarily curtailed. The New Prague facility manufactures aluminum dewars and is one of MVE Biological Solutions' three global manufacturing facilities. Cryoport expects to resume production at the New Prague facility during the week of February 14th and ramp up to full production during the first quarter. The company anticipates the revenue impact of $4M-$5M to be limited to the first quarter. Furthermore, the company expects its insurance to cover the majority of the costs to restore and re-open the facility, as well as related business interruption losses.

09:28 EST Purnovate announces in vivo data for PNV-5032 as potential asthma treatment - Purnovate announced in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model. PNV-5032 Relevant Information: Greater than 1000-fold selective over the adenosine A1 receptor in potency assays; Demonstrated solubility more than 100 times greater than other selective adenosine compounds of the same class currently known to the Company; Solubility of an inhaled product allows dissolution in the aerosolized mist for fine distribution over the bronchioles and can be important in facilitating bronchiole membrane penetration; Findings indicate drug development potential of molecules of this class, possibly to treat asthma; Covered by a composition of matter patent application for patent protection through 2042 with expected statutory extension to 2047. Study Design: Sheep, which respond to allergens and adenosine challenges in a manner similar to humans, were initially challenged with an aerosolized dose of Ascaris Sum allergens. Sheep are naturally allergic to these antigens, derived from intestinal roundworms, and each animal responded with severe bronchoconstriction, a clinically relevant symptom shared with asthma patients. After a washout/recovery period of a few weeks, PNV-5032 was nebulized and administered prophylactically to the sheep. Fifteen minutes later, the sheep received another aerosolized dose of Ascaris Sum allergens. Breath-by-breath determination of mean pulmonary flow resistance was measured with the esophageal balloon technique over four hours post challenge, corresponding to the early asthmatic reaction. Each animal served as its own control. Study Results: A significant 25% reduction in airflow resistance in the PNV-5032 group was observed as compared to the control group.

09:22 EST Bask Bank expands product set with high-yield interest savings account - Texas Capital Bancshares announced the expansion of its digital Bask Bank platform as a continuation of its overall product strategy. Texas Capital Bancshares, Inc. is building a full-service financial services firm with distinct capabilities to provide clients with solutions for their consumer, commercial, and investment banking needs. Bask Bank, as part of the overarching strategy, is evolving to service customers in search of a high-yield savings account for the cash component of their portfolios. The new Bask Interest Savings Account offers top-tier rates of return with an Annual Percentage Yield of 0.70%, compared to the national average of 0.06%.

09:20 EST Gaucho gets approval for Algodon Wine Estate plan in Mendoza, Argentina - Gaucho Group Holdings announced it received official approval from the Municipality of San Rafael of the masterplan for its Algodon Wine Estates, a 4,138 acre wine, wellness, culinary and sport resort and luxury residential development, in San Rafael, Mendoza, Argentina As previously announced, this stage of the masterplan was designed by the architectural planning and design firm EDSA, whose work spans more than 5,000 projects in over 100 countries. EDSA's vision for Algodon Wine Estates includes further building upon the estate's award-winning vineyard development by emphasizing the existing winery and 1946 vines, the local Mendocino culture, as well as the estate's existing terrain, amenities, and features. The masterplan includes development of an additional 200 lots, ranging in size from 2.47 acres to 12 acres. The company anticipates sales of these additional lots could ultimately generate more than $100 million in revenues. The centerpiece of the masterplan is an ultra-luxury 80-room hotel, that will also include 40-60 residences, for which Algodon Wine Estates seeks to co-develop with a world class luxury hospitality brand. The revenue potential from the hotel rooms and branded residences could generate an additional $25M per year. The expanded masterplan includes a 27-hole championship-style golf course, championship-style tennis facilities, centralized village center and sports club, and an equestrian facility that will include a horse riding and training center. Additional highlights from the plan include an organic farming area, as well as organic fruit orchards, a boutique distillery, organic/seasonal restaurants, lavender and rose gardens, as well as various hiking, mountain biking, and walking trails that connect the social and residential areas throughout the estate.

09:07 EST Genie Energy trading resumes

09:05 EST QuickLogic receives investment for approximately $1.48M - QuickLogic announced that current and new institutional investors have purchased, in separate private placement transactions, 310,000 shares, or 2.6% of the current shares outstanding, raising proceeds of approximately $1.48M. "We are pleased with the continued financial support we are receiving from both our long-time shareholders and investors who have followed QuickLogic for many years. They understand the tremendous opportunity we have with our Open Source initiatives," said CEO Brian Faith. "Following our recent announcement that we would be at or above operating cash breakeven in Q4, these investors again reached out to us wanting to further support our efforts. With our pipeline of business growing, this additional capital adds greater financial resources to quickly execute on our growth and profitability objectives."

09:04 EST Lam Research announces new suite of selective etch products - Lam Research announced a new suite of selective etch products that apply breakthrough wafer fabrication techniques and novel chemistries to support chipmakers in the development of gate-all-around (GAA) transistor structures. Composed of three new products - Argos, Prevos and Selis - Lam's selective etch portfolio provides a powerful advantage in the design and manufacture of advanced logic and memory semiconductor solutions.

09:03 EST Aerojet solid rocket monitor technology supports US army's LC-TERM program - Aerojet Rocketdyne has successfully tested an advanced solid rocket motor as part of the U.S. Army Low Cost Tactical Extended Range Missile, LC-TERM, Technology Program. Capabilities demonstrated under the LC-TERM program have applicability to the U.S. Army's Multiple Launch Rocket System, MLRS, family of munitions. "This successful test demonstrates Aerojet Rocketdyne's advanced propulsion capabilities that continue to position our warfighters with a superior technical advantage," said Eileen Drake, Aerojet Rocketdyne CEO and president. The static test, completed at the company's Camden, Arkansas site, demonstrated lower weight components and higher performance tactical propulsion technologies that can provide MLRS with extended-range capability. The solid rocket motor met all test requirements and performed as expected through the duration of the test.

09:01 EST HP Inc. announces expansion of HP Amplify Impact to 24 countries - HP Inc. announced the expansion of HP Amplify Impact to an additional 24 countries across Europe, Latin America, Asia Pacific and Japan. Now available in 43 countries around the globe, the first of its kind partner assessment, resource, and training program provides greater than 10,000 partners with the opportunity to join HP in its efforts to generate meaningful impact on Climate Action, Human Rights and Digital Equity.

08:58 EST Genie Energy authorizes share repurchase for up to $1M per quarter - Genie Energy's board has authorized the company to repurchase shares of its Series 2012-A Preferred Stock. The authorization is to purchase up to $1.0M per quarter at the liquidation preference of $8.50 per share beginning in Q2. There are approximately 2.3 million shares of Series 2012-A Preferred Stock outstanding with an aggregate liquidation preference of $19.7M. The preferred stockholders' rights to dividends on outstanding shares will not change during the buyback period.

08:54 EST Willdan Group awarded decarbonization contract from Utah State University - Willdan Group announced that Utah State University, or USU, has awarded it a contract to develop a strategic decarbonization plan for the USU central utility plant. As part of this contract, Willdan will identify and help prioritize a series of projects for construction that focus on the campus's central heating, cooling, and power generation systems. This contract is part of a larger initiative led by the USU Greenhouse Gas Reduction Steering Committee to accelerate the reduction of greenhouse gas emissions and become a carbon-neutral campus by 2050.

08:43 EST Synchrony partners with Mercyhealth for treatment financing - Synchrony and Mercyhealth, a regional health system with seven hospitals and 85 primary and specialty care locations, announced a multi-year strategic partnership to expand patient financing options. Mercyhealth will accept Synchrony's CareCredit credit card, for pre-care, point-of-care and post-care payment. Synchrony's CareCredit financing program is integrated into Mercyhealth's Epic MyChart patient management platform. With Synchrony's CareCredit, patients can apply for the credit card through Epic MyChart or on their mobile device, computer or over the phone, and find out within minutes if they have been approved.

08:39 EST CSP Inc. reactivates stock repurchase program for up to 194,000 shares - The Company re-activated the stock repurchase program on December 29, 2021 with authorization to buy up to 194,000 shares of the Company's common stock. The Company did not purchase any shares in the fiscal first quarter ended December 31, 2021.

08:38 EST BioMarin sells priority review voucher for $110M - BioMarin has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher it obtained in November 2021 for a lump sum payment of $110M. The company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of Voxzogo for Injection, indicated to increase linear growth in pediatric patients with achondroplasia five years of age and older with open epiphyses - growth plates - . The transaction remains subject to customary closing conditions, including anti-trust review. This is the third Priority Review Voucher that BioMarin has received. Management expects that the net gain on the sale of the PRV, after income taxes, will be incremental to the company's previously communicated expectation to earn positive GAAP net income in 2022.

08:37 EST Teva says 45% of 2022 revenue expected in 1H22, 55% in 2H

08:37 EST Blade teams with LA Rams for helicopter service for week leading up to game - Blade Air Mobility announced that it is partnering with the Los Angeles Rams to provide helicopter services to invited guests across the Los Angeles skyline and Stadium throughout the week. Guests will depart directly from the rooftop of the Rams' hospitality headquarters at Penthouse 56 hosted by Los Angeles Rams and SoFi in downtown Los Angeles, where the Rams will be hosting special events this week. As part of the partnership, Blade will also offer helicopter charter services to bypass Los Angeles gridlock between Los Angeles area airports such as Santa Monica, Van Nuys and Orange County and the rooftop helipad at the Rams' hospitality headquarters in downtown Los Angeles, where Blade will also construct an exclusive passenger lounge for Blade and Rams' guests.

08:36 EST Manhattan Associates' Manhattan Active Omni chosen by Penti - Manhattan Associates announced that Penti has chosen Manhattan Active Omni's unified commerce solution to help deliver a "customer-first, integrated omnichannel brand experience," the company said. Penti is Turkey's largest women's fashion retailer, with over 600 stores in 40 countries. The team at Penti chose Manhattan Active Omni to "provide seamless omnichannel capabilities across order orchestration, fulfilment optimisation, inventory availability, store fulfilment and point of sale," the company added. "Penti has ambitious goals in terms of geographic expansion and a cross-channel, unified commerce experience and we are looking forward to helping the team realise these growth ambitions through the power of Manhattan Active Omni. There is much more in store for this growing relationship, and we look forward to exploring the Manhattan Active suite of solutions further in the future too," finished Martin Lockwood, senior director at Manhattan Associates.

08:35 EST TILT exercises purchase option on Taunton, Massachusetts facility - TILT Holdings has signed a definitive agreement to exercise its purchase option for ownership of its Taunton, Massachusetts facility for a purchase price of approximately $13 million. Operating since August 2018, the Company's state-of-the-art Taunton facility, located at 30 Mozzone Boulevard, is comprised of a 100,000 square-foot building that includes cultivation, processing and a product manufacturing lab, as well as a 3,000 square-foot medical and adult-use dispensary. Through its subsidiary, Commonwealth Alternative Care, Inc., the Company has entered into the Purchase Agreement with the current owner of the Taunton facility. The Company expects the transaction to close on March 31, 2022. The Company paid an initial deposit of $50,000 into escrow upon execution of the Purchase Agreement, and will pay an additional $150,000 deposit into escrow if the Company elects to proceed with its acquisition of the facility after its 45-day due diligence review. The Taunton facility is comprised of two condominium units. The Company has until March 15, 2022 under the Purchase Agreement to elect to purchase both Unit A and Unit B or solely Unit A. If the Company elects to purchase Unit A only, the purchase price shall be reduced to approximately $4.6 million.

08:34 EST ABB, Paccar partner to provide PACCAR dealers, customers with charging solution - ABB (ABB) is partnering with PACCAR (PCAR) to provide PACCAR dealers and their customers with a range of advanced charging solutions across its fleet operations in North America and Europe. "Pairing ABB, a global leader in fleet electrification, with PACCAR, one of the largest manufacturers of medium- and heavy-duty trucks, is a strategic and sustainable partnership that will accelerate e-fleet expansion and adoption as well as reduce carbon and noise emissions in the transportation sector," said Frank Muehlon, President of ABB's E-mobility division. "Like PACCAR, ABB sees tremendous opportunity in electrifying the trucking industry and is committed to delivering safe, smart and sustainable electrification solutions for fleet charging."

08:32 EST Conduent completes sale of Midas Suite of Solutions to symplr - Conduent announced it has closed the sale of its Midas Suite of Solutions to symplr for a price of $340M less certain customary adjustments. The signing of the transaction was announced Jan. 4, 2022. Net proceeds, after payment of taxes and related expenses, are expected to be approximately $270M, and will be used for repayment of debt and investing in Conduent's business. As previously disclosed, the transaction is part of Conduent's ongoing strategy to focus on synergies within its portfolio to enhance shareholder and client value.

08:23 EST US Ecology trading halted, news pending

08:22 EST Teva hoping for FDA approval for schizophrenia drug in mid-2022, says CEO

08:21 EST CVS Health says entering 2022 with 'powerful momentum' - Says had another strong year of Medicare growth in 2021. Says has "clear pathway" to low double digit EPS growth over time. Comments taken from Q4 earnings conference call.

08:20 EST Equinor engages third party to conduct share repurchases - Equinor has on 9 February 2022 engaged a third party to conduct repurchases of the company's own shares to be used in the share-based incentive programs for employees and management for the period from 15 February 2022 until 13 January 2023. Shares acquired under the buy-back programme in the period from 15 February 2022 to 13 May 2022 is based upon the authorization from the annual general meeting on 11 May 2021 and registered in the Norwegian register for business enterprises. According to the authorization, the maximum number of shares to be purchased in the market is 15,200,000, the minimum price that can be paid for the shares is NOK 50, and the maximum price is NOK 500. Share buyback after the annual general meeting 2022 is subject to a new authorization. The buy-back programme is time-scheduled, and the share purchases shall take place on specific dates in the period from 15 February 2022 until 13 January 2023 with a determined purchase amount on each date, as set out in the buy-back programme. The total purchase amount under the share buy-back programme is NOK 1,413,000,000. The maximum number of shares to be acquired is 20,800,000 shares, of which up to 10,400,000 shares can be acquired in the period from 15 February 2022 to 13 May 2022, and up to 10,400,000 shares can be acquired in the period from 15 June 2022 to 13 January 2023. The shares shall be used to meet obligations towards employees who participate in the company's share saving program and the long-term incentive scheme.

08:17 EST Aptevo Therapeutics earns $10M milestone payment for Ruxience - Aptevo Therapeutics announced that the company has earned a $10M non-dilutive milestone payment related to 2021 sales of Ruxience. Additionally, based on Ruxience Q4 and full-year sales results, the company is optimistic about the possibility of earning additional non-dilutive milestones totaling $22.5M over the next two years. The company also announced that its Phase 1b trial evaluating lead drug candidate APVO436 for the treatment of acute myeloid leukemia, or AML, continues to enroll new clinical trial sites and that the first complete remission patient, announced in 2021, is proceeding to transplant.

08:17 EST Beam Global EV ARC selected for autonomous wildfire fighting exercise - Beam Global announced that Project Vesta, an unmanned fire control prototype that combines state-of-the art technology and Commercial Off The Shelf equipment has selected the EV ARC off-grid solar-powered EV charging and emergency power system to provide a critical component of an innovative fire mitigation system that networks autonomous air and ground vehicles, solar charging capabilities, fire response equipment and communications. The Project Vesta goal is persistent fire surveillance and analytics capabilities enabled by edge computing and rapid interoperability.

08:16 EST Amdocs announces expansion of 5G Value Plane offerings - Amdocs announced the expansion of its 5G Value Plane offerings to seamlessly serve emerging 5G standalone networks. By embedding cross-network automation across all aspects of the business, communications service providers can unlock the full potential of 5G.

08:14 EST Herc Holdings increases quarterly dividend by 15% to 57.5c per share - The Herc Holdings board of directors declared a quarterly dividend of 57.5c per share, payable to shareholders of record on February 23 , with a payment date of March 10. The Company inaugurated its first quarterly dividend payment of 50c per share in the fourth quarter of 2021. "We are pleased to start 2022 with a 15% increase in our quarterly dividend," said Larry Silber, president and chief executive officer. "We are committed to delivering long-term sustainable value to shareholders with a balanced, disciplined and opportunistic approach to capital deployment. With our available liquidity, we plan to continue to invest in organic growth and M&A and will consider future dividend growth in line with our long-term business performance." At the new rate, the indicated dividend on an annual basis is $2.30 per share compared to the previous rate of $2.00 per share.

08:13 EST Faraday Future enters partnership with Myoung Shin to manufacture FF 81 - Faraday Future announced that Myoung Shin, an automotive manufacturer headquartered in South Korea, has been contracted to manufacture Faraday Future's second vehicle, the FF 81, with SOP scheduled for 2024. The FF 81 is a luxury, mass-market electric vehicle from FF, with advanced connectivity and a user experience tailored to a wider audience than the ultimate intelligent techluxury FF 91, which is scheduled to launch in Q3 2022.

08:11 EST 4D Molecular announces updated interim results from 4D-310 Phase 1/2 trial - 4D Molecular Therapeutics announced updated interim clinical data from the ongoing Phase 1/2 clinical trial of 4D-310 in patients with Fabry disease at the 18th Annual WORLDSymposium. The data described are from the ongoing Phase 1/2 dose-escalation and dose-expansion clinical trial assessing intravenous 4D-310, 4DMT's targeted and evolved C102 vector-based product candidate designed for treatment of a broad Fabry disease patient population. The primary endpoint of the trial is safety and tolerability. Key secondary endpoints include change from baseline in serum AGA activity and serum lyso-Gb3 over time. The data cutoff date was January 13, 2022. Updated Interim Clinical Activity and Safety Results: Serum AGA overview: Following 4D-310 infusion, mean serum AGA enzyme activity was within, or significantly above, the normal range in all three patients, despite pre-treatment anti-AGA antibody positivity in all patients. Serum AGA activity over time in patients off of ERT: Updated serum AGA activity data show that following discontinuation of enzyme replacement therapy, AGA activity was stable at 14-fold mean normal at week 37 in Patient 1, and at 10-fold mean normal at week 20 in Patient 3. Patients 1 and 3 demonstrated an increase in serum AGA enzyme activity significantly above the normal range at all timepoints through last follow-up. Post-treatment serum AGA enzyme activity was well above the normal range at 139.7 nmol/hr/mL at week 37 and 98.8 nmol/hr/mL at week 20 in Patient 1 & 3, respectively. Cardiac imaging and cardiac-related quality-of-life: Initial clinical data suggests encouraging effects on cardiac endpoints. Patient 1 reached the initial 6-month cardiac MRI and echocardiogram endpoint assessments. Patient 1 experienced encouraging improvement beyond the minimal detectable difference on the cMRI native T1 signal, which is consistent with glycosphingolipid substrate reduction. All three patients experienced increases in quality-of-life scores using the Kansas City Cardiomyopathy Questionnaire. Safety and tolerability: 4D-310 continues to demonstrate a manageable safety profile. Of note, no cardiac toxicity has been reported as of the data cutoff. Cardiac safety was evaluated based on serial assessments of multiple blood biomarkers, electrocardiograms and echocardiograms.

08:10 EST CCC Intelligent Solutions acquires Safekeep - CCC Intelligent Solutions announced it has acquired Safekeep, an AI leader in subrogation claims management technology. Safekeep is an enterprise platform that leverages AI to speed and improve subrogation management across auto, property, workers' comp, and other insurance lines of business. The acquisition of Safekeep is a natural next step in CCC's vision to deliver end-to-end straight-through claims processing.

08:09 EST SAIC receives $410M contract - SAIC received $410M in contract awards from space and intelligence community organizations for the fourth quarter of fiscal year 2022, bringing the full fiscal year contract awards to $2B.

08:07 EST Teva: Settlement with Texas 'a good way forward' - CEO Kare Schultz sees nationwide settlement in next 12 months. Comments taken from Q4 earnings conference call.

08:07 EST Clever Leaves conducts review of operations to streamline organization - In support of the full year financial targets, the Company has conducted a review of its operations to streamline the organization and reduce expenses in a manner that aims to minimize the commercial impact. The Company has already made several changes, including workforce reductions, elimination of non-core programs, and postponement of sales or product development associated with longer-lead time commercial opportunities or geographies. The Company continues to evaluate its cash resources and need for additional capital, while focusing on generating cash through reducing working capital. The Company believes it is positioned to benefit from the completion of the capital-intensive phase of its growth by focusing on gaining commercial contracts, and improving its margins. As a result of this review, the Company has identified the following strategic growth objectives and key regions of focus for 2022: Australia: Capitalize on early traction with expansion of flower products and scale and secure additional extract sales agreements. Germany: Commence full commercial launch for the IQANNA flower brand, initiate sales of products through extract B2B partnerships, and activate import path for flower from our Portugal operation. Brazil: Activate sales agreements for products that have recently received regulatory approval and complete approval for other key products. Israel: Scale existing relationships for APIs and secure a large commercial-scale partnership for flower. United States: Commercially launch first CBD brand, JoySol. Colombia: Continue preparation for first flower sales, pending passage of final government resolutions. CEO Kyle Detwiler continued: "As we progress through 2022, we are working toward several commercial and regulatory milestones, which, if achieved, we expect will result in increased cannabinoid sales. Several regulatory or customer approval processes that were hampered by the pandemic now appear to be progressing. Having completed both construction and licensing on our Portugal cultivation expansion ahead of schedule in 2021, we are nearing completion on our capex cycle, which we believe positions us to maintain our disciplined approach to capital deployments. On the commercial front, our 2022 revenue expectations include the benefit from the cannabinoid product approvals we have obtained in Brazil. In 2022, we plan to continue our focus on ramping our existing supply partnerships and deepening our foothold within several international cannabis markets we believe have high potential. "To support our continued work on activating our commercial pipeline, we have identified six key strategic goals on which to focus our efforts in 2022. As of last month, we have already achieved progress on our first goal, having announced our entrance into the U.S. consumer CBD market with the launch of JoySol. In Germany, we continue to make progress towards commencing our full distribution of IQANNA following a successful soft launch of the product in the third quarter of 2021, and we are nearing several commercial and business development milestones with other B2B partnerships. We remain attentive to how regulatory standards evolve in the German market and across all of our core markets, particularly as we monitor product approvals in Brazil and the status of Colombia's resolutions dictating the timing and regulations surrounding dried flower exports. In Brazil, after lengthy product registration work to comply with strict pharmaceutical product registration protocols, we have seen a few of our partners receive special marketing authorization for cannabis products, which is one of the last milestones to accomplish before a partner can move to commercial-scale orders. "In Australia and Israel, we plan to continue working to ramp our existing supply agreements and grow our presence within these markets. With the gradual progress we have made in each market over the past year, we seek to maintain close collaborations with our current supply partners and identify additional commercial opportunities. While our work to achieve Clever Leaves' long-term vision remains ongoing, we believe our efforts to steadily execute on these objectives will continue to strengthen our commercial partnerships and overall presence within the global cannabinoid supply chain."

08:05 EST U.S. Steel breaks ground on next-gen $3B steel mill in Arkansas - United States Steel broke ground in Osceola, Arkansas on the company's next-generation highly sustainable and technologically advanced steel mill. The $3B steelmaking facility will be the most advanced in North America and largest private project in the history of Arkansas. "Several years ago, we embarked on a transformative vision for U. S. Steel," said U. S. Steel President & CEO David B. Burritt. "Now we celebrate, as we take another significant step forward in becoming the steel company of the future. This facility is engineered to bring together the most advanced technology, to create the steel mill of the future that delivers profitable sustainable solutions for our customers."

08:04 EST Fox Corp. board authorizes $4B stock repurchase program - The company has authorized a $4B stock repurchase program. To date, the company has repurchased $1.5B of its Class A common stock and $634M of its Class B common stock.

08:03 EST Tabula Rasa HealthCare to sell DoseMeRx solution - Tabula Rasa has signed a non-binding Letter of Intent to sell its DoseMeRx solution. DoseMeRx is an advanced precision dosing tool to help physicians and pharmacists accurately dose patients' high-risk medications based on individual needs, reducing risk, and improving patient outcomes.

08:02 EST Clever Leaves CEO Kyle Detwiler to step down, Andres Fajardo to succeed - Clever Leaves Holdings announced a leadership transition plan. Andres Fajardo, currently a director and president of the Company, has been selected to succeed Kyle Detwiler as CEO, effective March 24, 2022. Detwiler will remain CEO until March 24, 2022, to ensure a smooth transition, and he will continue to serve as the Company's Chairman until such date.

07:56 EST Teradata enters $250M accelerated share repurchase agreement - Teradata announced that it has entered into an accelerated share repurchase agreement with JPMorgan Chase Bank to repurchase $250M of the Company's common stock. The ASR was entered into as part of the company's previously announced $1B open market share repurchase authorization, under which approximately $913M will remain available after giving effect to the ASR. The company intends to fund the ASR from cash on hand.

07:52 EST Avrobio reports interim data from AVR-RD-04 trial - Avrobio reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 18th Annual WORLDSymposium in San Diego. The first three patients infused with AVR-RD-04 remain off oral cysteamine, with follow up durations ranging between 12- and 26-months post-gene therapy infusion. Sustained engraftment has been observed in each of these patients, as demonstrated by stable vector copy number, or VCN, levels. A fourth patient was infused in November 2021. No adverse events related to the drug product have been reported in the four patients infused to date. The collaborator-sponsored Phase 1/2 clinical trial is evaluating the safety and efficacy of AVR-RD-04 in adult patients who previously had been treated with cysteamine. AVR-RD-04 consists of the patient's own hematopoietic stem cells, genetically modified to express functional cystinosin, the protein that is deficient in people living with cystinosis. Interim VCN data indicate that the first three patients dosed have potentially reached a plateau 12- to 26-months post-gene therapy infusion at levels between 1 and 2. VCN per diploid genome. VCN/dg is the average number of copies of the transgene integrated into the cell genome and is used to help assess the long-term engraftment and thus durability of gene therapy. Skin and intestinal mucosa biopsies for the first three patients infused indicate a decline in the number of cystine crystals, with one-year reductions in average intracytoplasmic crystals per cell in skin ranging from 35% in patient 1, 64% in patient 2 and 81% in patient 3. In rectal biopsies, a 53% reduction was observed in patient 1 after 18 months, and 28% and 86% reductions were observed in patients 2 and 3, respectively, after 12 months. A hallmark of cystinosis is the accumulation of cystine in lysosomes, a type of cellular organelle, which leads to tissue and organ damage resulting in debilitating co-morbidities.

07:47 EST Cummins to acquire engine braking and cylinder deactivation company - Cummins (CMI ) announced the signing of an agreement to acquire Jacobs Vehicle Systems, a subsidiary of Altra (AIIMC) Industrial Motion Corp., and a supplier of engine braking, cylinder deactivation, start and stop and thermal management technologies. The agreement brings the addition of new technologies to provide growth opportunities for Cummins' current and future advanced diesel engine platforms. The acquisition of JVS also secures critical USMCA qualified engine components for current and aftermarket products and expands on Cummins Turbo Technologies' success with customers globally. "JVS brings engineering expertise, best in class products and key manufacturing capabilities to Cummins that will allow us to continue developing component technologies that deliver market leading performance and emissions," said Jennifer Rumsey, Cummins' President and Chief Operating Officer. "We expect that this transaction will provide both attractive financial returns and future growth opportunities for our company."

07:44 EST Siemens collaborates with Ford on F-150 Lightning charger - Siemens (SIEGY) announced it has worked with Ford (F) on the Ford Charge Station Pro, a custom electric vehicle, or EV, charger for the Ford F-150 Lightning. This innovative charger is the first bidirectional-ready EV solution set for release at retail customer scale to receive certification under the newly expanded Underwriters Laboratories, or UL, 9741. The new charge station also features a peak power of 19.2kW, achieving the maximum power rating currently available for a Level 2 charge station. The Ford Charge Station Pro is needed to enable Ford Intelligent Backup Power, a system that allows the Ford-150 Lightning to become an interactive part of the home and be used as a power generation source during outages, the first electric truck to do so.

07:37 EST Nordic American Tankers reports conclusion of two six-year time charters - The company said, "We are pleased to inform you that we have concluded two six-year Time Charters for our two Suezmax newbuildings for delivery in May and June this year. The contracts have been entered into with ASYAD Shipping Company and will commence upon delivery of the two NAT suezmaxes from the shipyard in South Korea. With the recent sales of two vessels, the NAT fleet now count 23 vessels. The time charter rates concluded will secure a stable revenue stream over the six years, and generate an aggregate revenue of more than USD 100 million during these charters. The cumulative cash flow, after operating expenses, from these contracts will equal in excess of 60 percent of the original price of the vessels. Thanks to the quality of our fleet and our maintenance schedules, the NAT suezmaxes are able to operate efficiently for more than 25 years. The origin of the NYSE listed Nordic American Tankers Ltd started out with three vessels on seven year charters back in 1997 and formed the back-bone of our growth and expansion. The contracts we now have concluded, are in line with our conservative policy of relying on both spot and long-term charter markets to navigate in the tanker business. Upon delivery of the two new-buildings, NAT will have a number of its vessels on long term charters. Contracts of a long term nature, is an insurance policy and is strengthening NAT. The other NAT ships trading in the spot market, will reap the benefits on that front as the market improves."

07:36 EST Teva CEO 'pleased' with agreement reached with Texas - Regarding the recently announced settlement in the opioid-related litigation in Texas, CEO Kare Schultz stated, "I'm very pleased with the agreement we reached with the state of Texas, the second most populous state in the U.S. Not only does it mark a further step in resolving our legacy opioids litigations more broadly, but importantly also makes critical medicines part of the solution when addressing the opioids epidemic. While the agreement includes no admission of wrongdoing, it remains in our best interest to put these cases behind us and continue to focus on the patients we serve every day."

07:35 EST CVS Health backs FY22 Health Care Benefits revenue view $88.1B-$89.6B - Backs total medical membership view 23.8M-24.1M. Backs FY22 Pharmacy Services revenue view $162.5B-$165.3B; total pharmacy claims processed 2.24B-2.27B. Backs FY22 Retail/LTC revenue view $99B-$100.7B; prescriptions filled 1.61B-1.64B.

07:33 EST Missfresh doubles sales during 2022 Chinese New Year holiday week - Missfresh reported that, compared with pre-holiday sales levels, the gross merchandise value generated on the Missfresh platform - on-demand retail sales - during the recent Chinese New Year holiday doubled during the week-long festival. Due to the resurgence of COVID-19 in China, many people chose to stay in the cities where they live and work during this CNY. Meanwhile, most families reduced large group gatherings in restaurants over the holiday period. As a result, online fresh grocery shopping and on-demand delivery service providers, such as Missfresh, were well placed to meet the surge in demand and diverse needs of stay-at-home catering. According to Missfresh's statistical data, sales of the Company's Ready-to-Cook, Ready-to-Heat, and Ready-to-Eat products increased 2.7 times during the CNY holiday compared with pre-holiday levels. Additionally, many users purchased fresh cut flowers during the CNY festival, resulting in 2.2 times sales growth of this category over the holiday period.

07:32 EST Altra Industrial enters agreement to sell Jacobs Vehicle Systems to Cummins - Altra Industrial Motion (AIMC) announced that it has entered into an agreement to sell its Jacobs Vehicle Systems business to Cummins (CMI) for $325M. The business generated approximately $193M in revenue in 2021. "Today's announcement is fully aligned with our strategy to focus Altra's portfolio on highly engineered products in the motion control and power transmission markets," said Carl Christenson, Altra's Chairman and Chief Executive Officer. "We believe that the sale of Jacobs Vehicle Systems to Cummins, a well-established leader in the heavy-duty trucking industry, will give the JVS business an opportunity to thrive with more strategically aligned ownership. I'd like to thank the team for their dedication and support and wish them all the best with their new owners." The transaction is subject to customary closing conditions, including receipt of required regulatory approvals, and the Company anticipates it will close by the end of the calendar year.

07:28 EST Tesla says California plans to sue over alleged discrimination, harassment - Tesla said on Wednesday the California Department of Fair Employment and Housing intends to file a lawsuit against the company alleging systematic racial discrimination and harassment. The lawsuit appears to be focused on alleged misconduct at its factory in Fremont, California, between 2015 and 2019, Tesla said in a statement. Tesla said: "Tesla strongly opposes all forms of discrimination and harassment and has a dedicated Employee Relations team that responds to and investigates all complaints. We also have a Diversity, Equity, and Inclusion team whose work is shown in this public report. Tesla has always disciplined and terminated employees who engage in misconduct, including those who use racial slurs or harass others in different ways. We recently rolled out an additional training program that reinforces Tesla's requirement that all employees must treat each other with respect and reminds employees about the numerous ways they can report concerns, including anonymously. Above all, Tesla continues to seek to provide a workplace that is safe, respectful, fair, and inclusive -all of which are vital to achieving our mission." Once the DFEH files its lawsuit, Tesla said it will be asking the court to pause the case and take other steps to ensure that facts and evidence will be heard. Reference Link

07:18 EST SSC Security Services to acquire Avante Logixx in cash, stock transaction - SSC Security Services Corp. (SECUF) announce that it has entered into a definitive arrangement agreement to acquire Avante Logixx (ALXXF), a Toronto-based provider of full service, elite security solutions for high-net-worth residential customers, as well as premium security protection for leading enterprise and commercial clients across Canada, through its operating subsidiaries Avante Security Inc. and Logixx Security, respectively. Pursuant to the terms of the Arrangement Agreement, SSC has agreed to acquire all of the issued and outstanding common shares of Avante by way of a statutory plan of arrangement under the Business Corporations Act. Under the terms of the Plan of Arrangement, holders of Avante Shares will receive a combination of cash and common shares in the capital of SSC, as follows: $0.52 per Avante Share in cash plus 0.4155 of an SSC Share for each Avante Share held. Based on the volume-weighted average price of the SSC Shares on the TSX Venture Exchange for the 20 trading days ending on February 8, 2022, the Share Consideration has an implied value of approximately $1.23 per Avante Share which, when added to the Cash Consideration, implies a total combined consideration of approximately $1.75 per Avante Share, or an aggregate equity value of approximately $37.1 million. In addition, SSC will assume approximately $9.4 million of Avante's senior funded debt, which excludes $8.264 million of principal amount of unsecured convertible debentures held by certain subsidiaries of Fairfax Financial Holdings Limited. The combined company is expected to be owned approximately 70% by current holders of SSC Shares, and approximately 30% by Avante Shareholders. Significant cost synergies are expected to be realized by eliminating the cost of maintaining both companies as separate publicly-traded entities, as well as the rationalization of duplicate overhead costs. Avante's board of directors formed a special committee of directors to negotiate and review the Transaction. The Avante Special Committee unanimously recommended that the Avante Board approve the Transaction and the Avante Board having received the recommendation of the Avante Special Committee, unanimously approved the Transaction and unanimously recommends that Avante Shareholders vote in favour of the Transaction. Certain Avante Shareholders, as well as each of the directors and officers of Avante who hold Avante Shares, and who, as of February 8, 2022, collectively hold approximately 17% of the Avante Shares, have entered into voting support agreements with SSC pursuant to which they have agreed to vote their Avante Shares in favour of the shareholder resolution approving the Transaction. Both the Avante Board and Avante Special Committee received an opinion from one of its financial advisors, Canaccord Genuity Corp., that, as of the date of such opinion and subject to the assumptions, limitations and qualifications set out in such opinion, and such other matters as Canaccord Genuity considered relevant, the Consideration to be received pursuant to the Transaction is fair, from a financial point of view, to the Avante Shareholders. SSC's board of directors unanimously approved the Transaction. The Transaction will be effected by way of a statutory plan of arrangement under the Business Corporations Act. The implementation of the Plan of Arrangement will be subject to Avante Shareholder approval at a special meeting of Avante Shareholders, which is expected to be held in the second calendar quarter of 2022. The Transaction is subject to the approval of at least 66 2/3% of the votes cast by Avante Shareholders at the Special Meeting; the TSXV; the Ontario Superior Court of Justice; and is also subject to certain other closing conditions customary to a Transaction of this nature. Assuming all of the requisite court, shareholder and other approvals are received, SSC and Avante expect the Transaction to be completed during the second calendar quarter of 2022. Upon closing of the Transaction, Avante will become a wholly-owned subsidiary of SSC, with plans to transition ASI and LSI to directly-owned, independent subsidiaries of SSC. ASI and LSI will continue to operate as is, providing high-quality security and peace of mind to their customers. n recognition of the extensive security industry experience and contacts of Craig Campbell, Avante's CEO, Craig has been invited to join the SSC Board upon closing of the Transaction. The SSC Board will increase in number from five directors to six.

07:14 EST Tilray expands distribution across California - SweetWater Brewing Company has announced its expansion across the state of California with distribution partners, Reyes Beer Division, tying together the continued westward expansion of the SweetWater brand with the opening of SweetWater Colorado Brewing Company in Fort Collins, Colorado, and the recent acquisition of San Diego beer brands, Alpine Beer Company and Green Flash Brewing Company. With this expansion, the nation's 11th largest craft brewer will now be available for purchase throughout the state at local restaurants, bars, grocery chains, liquor stores and other retail establishments either on draft or in cans. "Having been born and raised on the West Coast, twenty-five years ago I had the fantastic opportunity to bring a piece of home with me to the East Coast through a slew of SweetWater's West Coast-style beers over the years," said Freddy Bensch, co-founder and CEO of SweetWater. "I am beyond stoked to have found our way across the U.S. to California, our OG stomping grounds, where we will continue to leverage the 420 lifestyle and SweetWater brand in its truest and purest form."

07:12 EST CME Group reports Q4 ADV 20.5M contracts, up 26% y/y - Fourth-quarter 2021 average daily volume was 20.5M contracts, up 26% versus fourth-quarter 2020. Non-U.S. ADV for full-year 2021 reached a record 5.5M contracts, up 4% compared with the same period in 2020.

07:10 EST IGM Biosciences advances IGM-6268 into clinical trials to treat COVID-19 - IGM Biosciences announced its progress in two Phase 1 clinical trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, for the treatment and prevention of COVID-19. The first, a Phase 1 clinical trial in the U.S., is a single and multiple ascending dose study to assess the safety, tolerability, and pharmacokinetics of IGM-6268 administered intranasally in healthy volunteers. The first two dose cohorts of healthy volunteers have been successfully cleared in the U.S., and data from the study are expected in the first half of 2022. The second, a Phase 1a/1b clinical trial in South Africa, is a study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of IGM-6268 administered intranasally first in healthy volunteers, once an appropriate dose cohort has been cleared, in outpatients with mild to moderate COVID-19. The first dose cohort of healthy volunteers has been cleared in the South Africa study, and data from the study are expected in mid-2022. IGM also announced that results from in vitro pseudovirus testing conducted by a widely recognized, commercial laboratory indicate that IGM-6268 exhibits neutralization of the Omicron variant at an IC50 of 230 ng/mL, as well as potent in vitro neutralization activity against all other SARS-CoV-2 Variants of Concern and Variants of Interest tested to date, including the Delta variant. This indicated IC50 for the Omicron variant is expected to be well below the concentrations achievable by intranasal administration in key sites of infection and viral replication, based on previous observations from animal studies.

07:06 EST Medicenna Therapeutics expects cash to fund operations through end of 2022 - Medicenna had cash, cash equivalents, and marketable securities of $23.4 million at December 31, 2021. These funds provide the Company with sufficient capital to execute its current planned expenditures through to the end of calendar 2022 and important upcoming catalysts based on its current plans and projections.

07:03 EST M3-Brigade Acquisition II, Syniverse terminate merger agreement - M3-Brigade Acquisition II Corp. announced that it has terminated its merger agreement with Syniverse by mutual agreement of all relevant parties. As a result, the special meeting of MBAC stockholders to approve the proposed transaction has been cancelled and MBAC will seek an alternative business combination. Mohsin Meghji, the CEO of MBAC, said, "We are disappointed that recent changes in market conditions made it impossible to consummate our proposed merger, but Syniverse is a great company with a strong management team and we are confident that it has a very bright future." The rate of MBAC stockholder redemptions for the proposed transaction would have exceeded the minimum condition for closing. "Although the parties collaboratively sought potential solutions in anticipation of high redemptions as a result of the recent turbulence in capital markets and growth stocks, these same conditions prevented the parties from reaching agreement on modifying the transaction terms," said Donald E. Morgan III, the Founder, Managing Partner and Chief Investment Officer of Brigade Capital Management, LP. "Nobody on the MBAC team is happy to have a failed deal and rest assured that we will have alternative sources of financing in hand for our next proposed combination," he continued. MBAC closed its initial public offering on March 8, 2021 and has 24 months from such date to complete its initial business combination.

06:51 EST Crown Castle increasing annual dividend 50% to 12c per share - Crown Castle is increasing its annual dividend for 2022 by 50% to 12c per common share, payable on December 15 to shareholders of record on November 30.

06:49 EST Albemarle in discussions with Mineral Resources to expand lithium joint venture - Albemarle announced that it has signed a non-binding letter agreement with Mineral Resources to explore a potential expansion of the MARBL Lithium Joint Venture, or MARBL. The non-binding letter envisions certain key principles, including: ownership of the Wodgina mine would change from 60/40 ALB/MIN to 50/50. Ownership of Kemerton I/II would remain 60/40. Albemarle would supply Greenbushes spodumene for use at Kemerton. Potential new 50/50 joint venture to own additional lithium conversion asset(s) outside of Australia to be jointly funded 50/50 by MRL and Albemarle. Albemarle would be the operator of these assets. Albemarle would remain the exclusive marketer of lithium products for the JV(s). The transactions contemplated by the non-binding letter agreement are subject to due diligence and the parties entering into binding agreements to effect the proposed transactions.

06:41 EST GlaxoSmithKline sees FY Specialty Medicines sales up 10% at CER - GSK said: "In 2022, we expect to continue to deliver on our strategic priorities. We plan to increase targeted investment in R&D, to build on and invest behind our top line momentum for key growth drivers and to deliver the demerger of our Consumer Healthcare business in mid-year. Assuming global economies and healthcare systems approach normality as the year progresses, we expect sales of Specialty Medicines to grow approximately 10% at CER and sales of General Medicines to show a slight decrease, primarily reflecting increased genericization of established Respiratory products. Vaccines sales are expected to grow at a low teens percentage at CER for the year as a whole. However, governments' prioritization of COVID-19 vaccination programs and ongoing measures to contain the pandemic are expected to result in some continued disruption to adult immunizations, with the impact weighted to the first half. For Shingrix, despite the potential for short-term pandemic disruption, we continue to expect strong double-digit growth and record annual sales based on strong demand in existing markets and geographical expansion."

06:33 EST Nice partners with Etisalat Digital on CXone Cloud platform - Nice announced a partnership with Etisalat Digital to drive the availability of the CXone platform in the United Arab Emirates. The collaboration provides Etisalat customers with a clear, seamless path to the cloud with CXone while enabling frictionless digital self-service and agent-assisted customer experiences. With CXone, Etisalat Digital is uniquely positioned to advise and empower organizations to transform their business via effective, engaging customer communications now and into the future. Nice CEO, Barak Eilam, and Etisalat Enterprise Digital CEO, Salvador Anglada, were present at the signing ceremony held at the Etisalat Digital Hospitality Lounge at Expo 2020, Dubai.

06:08 EST Clean Energy and Enbridge partner to supply CNG to UPS Canada Fleet - Clean Energy (CLNE), along with its industry partner Union Energy Solutions, an unregulated affiliate of Enbridge Gas - an Enbridge (ENB) company, has signed an agreement to fuel United Parcel Service - UPS - Canada delivery fleet vehicles with compressed natural gas - CNG - at its London, Ontario station. UPS Canada has converted 25 package delivery vans to operate on CNG - a lower carbon alternative to gasoline. The Clean Energy-operated CNG fueling station, located near the UPS facility in London, will provide an anticipated 525,000 gasoline gallon equivalent of CNG in a multi-year agreement. In further growth of CNG volume in Canada, the City of London has expanded its natural gas solid waste fleet from six to eight refuse vehicles, with plans to order more in the near future.

05:27 EST Allot Ltd. enters collaboration agreement with Amazon Web Services - Allot Ltd. announced a strategic collaboration agreement with Amazon Web Services, or AWS. The relationship will enable CSPs to deploy new Allot cloud-native application workloads on AWS and expand their existing Allot deployments. The strategic collaboration will enhance the ability of CSPs to leverage the full suite of Allot cloud-native applications on AWS, providing a consistent and scalable operating model for 5G cloud-based networks and services. Allot has already deployed a solution using the AWS cloud platform for a CSP customer in North America.

05:20 EST ICL sees FY22 adjusted EBITDA $1.85B-$2.05B - The company said, "ICL full year 2022 adjusted EBITDA is expected to be within a range of $1,850 million to $2,050 million, of which EBITDA of $875 million to $925 million coming from its specialties focused businesses.(1a) The company's fourth quarter 2021 dividend of 13.18 cents per share, or approximately $169 million, will be payable on March 8, 2022, to shareholders of record as of February 23, 2022."